Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) EV-to-EBIT

: 0.61 (As of Today)

View and export this data going back to 1993. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fresh Tracks Therapeutics's Enterprise Value is $-3.49 Mil. Fresh Tracks Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.69 Mil. Therefore, Fresh Tracks Therapeutics's EV-to-EBIT for today is 0.61.

The historical rank and industry rank for Fresh Tracks Therapeutics's EV-to-EBIT or its related term are showing as below:

FRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.82 Med: 0.18 Max: 2.6
Current: 0.61

During the past 13 years, the highest EV-to-EBIT of Fresh Tracks Therapeutics was 2.60. The lowest was -8.82. And the median was 0.18.

FRTX's EV-to-EBIT is ranked better than
73.2% of 444 companies
in the Biotechnology industry
Industry Median: 8.325 vs FRTX: 0.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Fresh Tracks Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-5.62 Mil. Fresh Tracks Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.69 Mil. Fresh Tracks Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 101.28%.

Fresh Tracks Therapeutics EV-to-EBIT Historical Data

The historical data trend for Fresh Tracks Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-0.05

-0.58

-0.01

0.19

0.99

Fresh Tracks Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															0.19	0.43	0.28	0.70	0.99

Competitive Comparison

For the Biotechnology subindustry, Fresh Tracks Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh Tracks Therapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's EV-to-EBIT falls into.

Fresh Tracks Therapeutics EV-to-EBIT Calculation

Fresh Tracks Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-3.493	/	-5.689
	=	0.61

Fresh Tracks Therapeutics's current Enterprise Value is $-3.49 Mil.
Fresh Tracks Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.69 Mil.

Fresh Tracks Therapeutics (OTCPK:FRTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Fresh Tracks Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-5.689	/	-5.616863179
	=	101.28 %

Fresh Tracks Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-5.62 Mil.
Fresh Tracks Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.69 Mil.

Fresh Tracks Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301

Website

https://www.frtx.com

Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Executives

Monica E. Luchi	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy	director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy	officer: General Counsel and CCO	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha	officer: Chief Research & Dev. Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant	director	10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton	officer: Chief Accounting Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown	director, officer: Chief Executive Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer	officer: COO and Secretary	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru	director	C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii	officer: Chief Financial Officer
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja	officer: Chief Medical Officer	121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy	officer: Chief Business Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju	director	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301